Clinical trials
Completed Phase 2 trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,259 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 10 |
| 2004 | 20 |
| 2005 | 22 |
| 2006 | 35 |
| 2007 | 45 |
| 2008 | 78 |
| 2009 | 87 |
| 2010 | 79 |
| 2011 | 90 |
| 2012 | 75 |
| 2013 | 69 |
| 2014 | 66 |
| 2015 | 76 |
| 2016 | 65 |
| 2017 | 76 |
| 2018 | 59 |
| 2019 | 59 |
| 2020 | 70 |
| 2021 | 75 |
| 2022 | 41 |
| 2023 | 33 |
| 2024 | 19 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 1,259 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Samsung Medical Center | 71 |
| Seoul National University Hospital | 71 |
| Asan Medical Center | 65 |
| Novartis Pharmaceuticals | 63 |
| Pfizer | 61 |
| Yonsei University | 45 |
| GlaxoSmithKline | 41 |
| Boehringer Ingelheim | 37 |
| Hoffmann-La Roche | 34 |
| Eli Lilly and Company | 31 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 93 |
| Stomach Neoplasms | 53 |
| Breast Neoplasms | 52 |
| Carcinoma, Hepatocellular | 39 |
| Lung Neoplasms | 30 |
| Asthma | 29 |
| Neoplasm Metastasis | 29 |
| Neoplasms | 29 |
| Colorectal Neoplasms | 26 |
| Recurrence | 24 |
Trials
Showing 1 to 25 of 1,259. Each trial links to its page on Pharma Observatory.
1,159 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.